Login / Signup

Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?

Roberto MorettoAndrew ElliottDaniele RossiniRossana IntiniVeronica ConcaFilippo PietrantonioAndrea Sartore-BianchiCarlotta AntoniottiCosimo RasolaMario ScartozziMassimiliano SalatiNicoletta PellaMaria Alessandra CalegariMartina CarulloFrancesca CortiGianluca MauriAngelo Paolo Dei TosGianluca MasiPavel BrodskiyHeinz-Josef LenzAnthony ShieldsSara LonardiMichael KornChiara Cremolini
Published in: British journal of cancer (2022)
Real-life data support the use of FOLFOXIRI ± bevacizumab only in BRAFV600E-mutated mCRC patients with right-sided tumours.
Keyphrases
  • metastatic colorectal cancer
  • squamous cell carcinoma
  • small cell lung cancer
  • electronic health record
  • wild type
  • big data
  • machine learning